High intraindividual week-to-week variability in BASDAI and BASFI values: Are several evaluations needed before starting or stopping TNFα antagonist therapy for spondyloarthropathies?

Joint Bone Spine

Volumn 75, Issue 2, 2008, Pages 167-171

  Berthelot, Jean Marie ^a   Tortellier, Lætitia ^a   Lavy Bregeon, Delphine ^a   Le Goff, Benoît ^a   Maugars, Yves ^a  

^a HÔTEL DIEU   (France)

Author keywords

Ankylosing spondylitis; Anti TNF; BASDAI; BASFI; Fluctuation; Monitoring; Spondylarthritis; Spondyloarthropathy; Variation

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; RETROSPECTIVE STUDY; SPONDYLOARTHROPATHY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40949122758     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.05.018     Document Type: Article

References (17)

1. Dernis E., Lavie F., Pavy S., et al. Clinical and biological evaluation in the management of ankylosing spondylarthritis patients: recommendations for clinical practice based on data from the literature and expert opinion. Rev Rhum 73 (2006) S13-S25
2. Maravic M., and Fermanian J. Psychometric properties of the bath ankylosing spondylitis disease activity index (BASDAI): comparison of the different versions available in English. Clin Exp Rheumatol 24 (2006) 79-82
3. Braun J., Pham T., Sieper J., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 817-824
4. Pham T., Guillemin F., Claudepierre P., et al. TNF-alpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 73 (2006) 547-553
5. Cohen J.D., Cunin P., Farrenq V., et al. Estimation of the Bath Ankylosing Spondylitis Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 33 (2006) 79-81
6. Claudepierre P., Flipo R.M., Sibilia J., et al. Patient knowledge of their disease: a French multicenter study in ankylosing spondylitis. Joint Bone Spine 71 (2004) 550-556
7. Heikkila S., Ronni S., Kautiainen H.J., et al. Functional impairment in spondyloarthropathy and fibromyalgia. J Rheumatol 29 (2002) 1415-1419
8. Wendling D. Ankylosing spondylitis without radiological sacroiliitis: a (re)current problem. Joint Bone Spine 73 (2006) 584-586
9. Godfrin B., Zabraniecki L., Lamboley V., et al. Spondylarthropathy with entheseal pain. A prospective study in 33 patients. Joint Bone Spine 71 (2004) 557-562
10. Pham T., Landewe R., van der Linden S., et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 65 (2006) 1620-1625
11. Kvien T.K., Mowinckel P., Heiberg T., et al. Performance of health status measures with a pen based personal digital assistant. Ann Rheum Dis 64 (2005) 1480-1484
12. Mowinckel P., Hagen K.B., Heiberg T., et al. Repeated measures in rheumatoid arthritis (RA) can effectively reduce the between subject variation and thereby the sample size in clinical trials. Ann Rheum Dis 11 Suppl (2006) 97 (abstract OP-0142)
13. Tubach F., Pham T., Skomsvoll J.F., et al. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum 55 (2006) 960-963
14. Dougados M., Gueguen A., Nakache J.P., et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 38 (1999) 235-244
15. Wendling D., Materne G.E., Michel F., et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 72 (2005) 309-312
16. Yazici Y., Barnes J.P., and Hines P.L. Changing patterns of anti-TNF medication use in 9074 rheumatoid arthritis patients between 2000-2005: shorter treatment duration and quicker switching between anti-TNF agents, with less than 50% of patients still on initial anti-TNF medication at 2 years. Arthritis Rheum 9 Suppl (2006) S-350
17. Gossec L., Le Henanff A., Breban M., et al. Continuation of treatment with infliximab in ankylosing spondylitis: 2-year open follow-up. Rheumatology (Oxford) 45 (2006) 859-862